SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer

被引：4
|
作者：
Westin, Shannon [1 ]
Kurnit, Katherine [2 ]
Fellman, Bryan [1 ]
Bhosale, Priya [1 ]
Hong, David [1 ]
Karp, Daniel [1 ]
Naing, Aung [1 ]
Pant, Shubham [1 ]
Piha-Paul, Sarina [1 ]
Fu, Siqing [1 ]
Rodon, Jordi [1 ]
Yap, Timothy [1 ]
Dumbrava, Ecaterina [1 ]
Sood, Anil [1 ]
Shafer, Aaron [1 ]
Soliman, Pamela [1 ]
Gershenson, David [1 ]
Kabil, Nashwa [3 ]
Coleman, Robert [4 ]
Mills, Gordon [5 ]
Meric-Bernstam, Funda [1 ]
机构：
[1] UT MD Anderson Canc Ctr Houston, Houston, TX USA
[2] Univ Chicago, Coll Med, Chicago, IL USA
[3] AstraZeneca, Gaithersburg, MD USA
[4] US Oncol Res, The Woodlands, TX USA
[5] OHSU, Portland, OR USA
来源：
GYNECOLOGIC ONCOLOGY | 2023年 / 176卷
关键词：
D O I：
10.1016/j.ygyno.2023.06.511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA 9
引用
下载
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations
    Kurnit, Katherine C.
    Meric-Bernstam, Funda
    Hess, Kenneth
    Coleman, Robert L.
    Bhosale, Priya
    Savelieva, Katerina
    Janku, Filip
    Hong, David
    Naing, Aung
    Pant, Shubham
    Rodon, Jordi
    Yap, Timothy A.
    Sood, Anil K.
    Soliman, Pamela T.
    Gershenson, David M.
    Mills, Gordon B.
    Westin, Shannon N.
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie P.
    Tanyi, Janos Laszlo
    Latif, Nawar A.
    Morgan, Mark Aloysuis
    Torigian, Drew A.
    Pagan, Cheyenne
    Rodriguez, Diego
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Le-Ming
    Smith, Simon
    Dean, Emma
    Armstrong, Deborah Kay
    Gaillard, Stephanie
    Simpkins, Fiona
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancer
    Lin, Z. P.
    Zhu, Y. L.
    Huang, P. H.
    Ratner, E. S.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 74 - 74
  • [4] Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor- Resistant Homologous Recombination-Deficient Ovarian Cancer
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie
    Tanyi, Janos L.
    Latif, Nawar
    Morgan, Mark
    Torigian, Drew A.
    Rodriguez, Diego
    Smith, Simon A.
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei -Ting
    Armstrong, Deborah K.
    Gaillard, Stephanie
    Giuntoli, Robert
    Simpkins, Fiona
    CLINICAL CANCER RESEARCH, 2023, 29 (15) : 2800 - 2807
  • [5] Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
    Lin, Z. Ping
    Zhu, Yong-Lian
    Lo, Ying-Chun
    Moscarelli, Jake
    Xiong, Amy
    Korayem, Yasmin
    Huang, Pamela H.
    Giri, Smith
    LoRusso, Patricia
    Ratner, Elena S.
    PLOS ONE, 2018, 13 (11):
  • [6] Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
    Do, Khanh T.
    Kochupurakkal, Bose
    Kelland, Sarah
    de Jonge, Adrienne
    Hedglin, Jennifer
    Powers, Allison
    Quinn, Nicholas
    Gannon, Courtney
    Vuong, Loan
    Parmar, Kalindi
    Lazaro, Jean-Bernard
    D'Andrea, Alan D.
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4710 - 4716
  • [7] Preclinical Evaluation of the PARP Inhibitor, Olaparib, in Combination With Cytotoxic Chemotherapy in Pediatric Solid Tumors
    Norris, Robin E.
    Adamson, Peter C.
    Nguyen, Vu T.
    Fox, Elizabeth
    PEDIATRIC BLOOD & CANCER, 2014, 61 (01) : 145 - 150
  • [8] PRECLINICAL STUDIES OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IMATINIB IN BRCA STRATIFIED OVARIAN CANCER
    Matheson, E.
    Salehan, M.
    Mukhopadhyay, A.
    Curtin, N. J.
    Drew, Y.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 673 - 673
  • [9] Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
    Ivy, S. Percy
    Liu, Joyce F.
    Lee, Jung-Min
    Matulonis, Ursula A.
    Kohn, Elise C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 597 - 611
  • [10] Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer
    Westin, S.
    Litton, J.
    Williams, R.
    Soliman, P.
    Frumovitz, M.
    Schmeler, K.
    Jazaeri, A.
    Sood, A.
    Lu, K.
    Moulder, S.
    Murthy, R.
    Rodriguez, A.
    Samuel, C.
    Engerman, L.
    Cyriac, A.
    Rugman, P.
    Lindemann, J.
    McMurtry, E.
    Mills, G.
    Coleman, R.
    ANNALS OF ONCOLOGY, 2017, 28
12345